



25 September 2024

Argent BioPharma Ltd.
(Argent BioPharma or the Company)

Date of AGM and Closing Date for Director Nominations

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, advises that in accordance with ASX Listing Rule 3.13.1, that the Company's Annual General Meeting is planned to be held on Thursday, 28 November 2024.

The closing date for receipt of nominations for persons wishing to be considered for election as a director is, 10 October 2024. Any nominations must be received at the Company's registered office no later than 5.00pm (WST) on 10 October 2024.

—Ends—

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Limited (the “**Company**”) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector. The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the central nervous system (“CNS”) and Immunology treatments.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

Phone

+61 8 6555 2950

Email

info@argentbiopharma.com

Address

Suite 1, 295 Rokeby Road, Subiaco, WA 6008,
Australia